Pelacarsen (formerly known as AKCEA-APO(a)-LRx or TQJ230) is an investigational medication developed by Ionis Pharmaceuticals and licensed to Novartis. It is engineered specifically to lower elevated levels of Lipoprotein(a)—commonly referred to as Lp(a).
Because high Lp(a) is predominantly genetically determined and largely resistant to diet, exercise, or standard statin therapy, pelacarsen represents a potential therapeutic breakthrough for managing residual cardiovascular risk.
How Pelacarsen Works
Lp(a) is a complex particle made up of an LDL-like core attached to a specific protein called apolipoprotein(a), or apo(a).
Mechanism: Pelacarsen is a second-generation antisense oligonucleotide (ASO). It works at the genetic messenger level inside liver cells (hepatocytes) by binding directly to the messenger RNA (mRNA) produced by the LPA gene.
Effect: By causing the target mRNA to be degraded before it can be translated, pelacarsen shuts down the liver’s ability to produce apo(a). Without apo(a), the body cannot assemble or secrete new Lp(a) particles.
Targeting: It is conjugated with GalNAc (N-acetylgalactosamine), a molecule that binds to specific receptors on liver cells. This targeted delivery allows the drug to be highly potent at lower doses while minimizing side effects elsewhere in the body.
Key Clinical Results & Effectiveness
Lp(a) Reduction: In Phase 2 clinical studies, monthly injections of pelacarsen achieved 65% to 80% reductions in circulating Lp(a) levels compared to placebo.
Impact on Other Lipids: Standard laboratory blood tests initially showed a drop in LDL (“bad”) cholesterol. However, further research revealed that this was primarily due to removing the cholesterol component contained within Lp(a) particles, rather than a direct reduction in true LDL particles.
Administration: It is designed as a once-monthly subcutaneous (under-the-skin) injection.
Current Clinical Development: The HORIZON Trial
While lowering a lab number is promising, regulatory agencies require proof that reducing Lp(a) translates directly into fewer heart attacks and strokes.
The Trial: The flagship Lp(a) HORIZON Phase III trial (enrolling over 8,000 participants with established cardiovascular disease and elevated Lp(a)) is evaluating whether an 80 mg monthly dose reduces major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death.
Timeline: Phase 3 cardiovascular outcomes data and subsequent regulatory filings are key milestones being closely watched by the cardiology community.
Safety Profile & Considerations
Tolerability: In clinical trials conducted thus far, pelacarsen has generally been well tolerated.
Side Effects: The most common side effect reported is mild to moderate injection-site reactions (such as redness, discomfort, or swelling where the shot is given).
Target Specificity: Nucleic acid-based drugs like ASOs have low rates of off-target biochemical interactions compared to traditional small-molecule drugs.
Pelacarsen is not yet approved by the FDA.
The expected timeline for FDA submission and potential commercial availability relies on the ongoing Phase 3 Lp(a) HORIZON cardiovascular outcomes trial:
Expected Approval & Launch Timeline
Phase 3 Data Readout: Topline results from the Phase 3 trial (enrolling over 8,000 patients) are slated for release.
FDA Submission: Novartis and Ionis plan to submit their New Drug Application (NDA) to the FDA shortly after data readout, targeted for the second half of 2026.
Potential FDA Approval & Availability: Standard FDA review for a major cardiovascular outcomes NDA typically takes 6 to 10 months. Assuming a smooth review, FDA approval could arrive around mid-to-late 2027, which is when the drug would become commercially available to patients.
To find your Lp(a) (Lipoprotein(a)) results on a lab report, it helps to know where—and how—it is usually reported.
Which Panel Is It On?
It is usually NOT on a Standard Lipid Panel: A basic cholesterol test only lists Total Cholesterol, LDL-C (“bad”), HDL-C (“good”), and Triglycerides.
Look for “Advanced” or Standalone Tests: Lp(a) is typically ordered as a specific standalone test or as part of an Advanced Lipid Panel, Cardiovascular Risk Panel, or brand-name tests like Quest’s Cardio IQ or Labcorp’s NMR LipoProfile.
How Is It Labeled on the PDF/Portal?
Search or scan your patient portal (like MyChart, Quest, or Labcorp) for the following exact names:
Lipoprotein (a) or Lipoprotein(a)
Lp(a)
Lp(a) Mass or Lp(a) Molar Concentration